Medical Cannabis and Epilepsy: The Evidence Base
This evidence summary provides a comprehensive, research-based review of the role of medical cannabis in epilepsy. Written for clinicians, educators, healthcare professionals and informed readers, it brings together current scientific understanding, clinical evidence and real-world outcomes in one accessible resource.
The publication examines how cannabinoids - particularly CBD - affect seizure disorders, with a strong focus on treatment-resistant epilepsy. It reviews nearly 100 clinical trials, observational studies and real-world data, providing a robust foundation for understanding both efficacy and safety. It also explores the practical challenges patients face in accessing CBMPs within the UK’s highly regulated system, including limited NHS prescribing, reliance on private clinics, and the significant financial burden placed on families.
With in-depth discussion of the mechanisms of action, drug interactions, paediatric considerations and the role of real-world evidence, this volume offers a clear and up-to-date scientific reference for clinicians integrating CBMPs into epilepsy care. It forms part of the wider MCCS Evidence Base Series and includes 250 references.
Content includes:
- Overview of epilepsy, seizure classification, causes and clinical presentation
- Mechanisms of action showing how cannabinoids influence neuronal excitability and seizure activity
- Evidence for CBD, THC and whole-plant formulations
- Use of THC in children with epilepsy and review of available safety data
- Second-generation cannabinoid-based medicines and their potential role
- Drug–drug interactions with conventional anti-seizure medications
- Importance of real-world evidence alongside clinical trials
- Extensive review of scientific literature with over 280 referenced studies
- Summary of UK and international guideline positions
- Areas for further research and limitations of current evidence
Format: Digital PDF
Length: 124 pages
Authors: Prof Mike Barnes & Hannah Deacon
Publisher: Medical Cannabis Clinicians Society (2025)
FAQ
Who is this publication for?
This evidence summary is intended for clinicians, pharmacists, nurses, educators and informed readers seeking a clear scientific overview of the evidence for medical cannabis in epilepsy.
Does the publication cover THC use in children?
Yes. It reviews available evidence on THC in paediatric epilepsy, addressing safety concerns and outlining what current research supports.
What types of epilepsy are discussed?
The publication focuses on treatment-resistant epilepsies in both adults and children, drawing on clinical trials, case series and real-world data.
Does it explain how cannabinoids work?
Yes. It details the mechanisms by which CBD, THC and other cannabinoids may reduce seizure frequency through effects on GABA, glutamate and other pathways.
Does the publication review safety and interactions?
It includes an overview of adverse effects, drug–drug interactions, CYP450 metabolism, and practical considerations when combining CBMPs with standard anti-seizure medications.
How does this differ from general epilepsy resources?
This publication focuses specifically on the evidence for medical cannabis in epilepsy, providing an independent, research-grounded reference aligned with UK clinical practice.
Is the content independent?
Yes. It is produced by the Medical Cannabis Clinicians Society and is based on published research, expert clinical insight and current UK guidance.